Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Biotech startup iECURE is based on work from the University of Pennsylvania scientist, who has been researching ways to use in vivo gene editing as a way to “knock in” healthy versions of a gene to treat rare liver diseases. The company, which will develop therapeutic candidates from Penn, has raised $50 million in Series A financing.
As part of MedCity's 2021 INVEST conference, Cesar de la Fuente, presidential assistant professor at the University of Pennsylvania, explains the value of the rapid low-cost diagnostic test he has developed to detect SARS-CoV-2 and how the platform technology can be deployed to detect other diseases cost-effectively.
A review published in JAMA found that bills introduced into the House and Senate don't go nearly as far as existing drug pricing regulations other countries. The researchers listed eight key lessons from six nations.
The project will bring in 29 institutions from North America, Europe and India and will use privacy-preserved data to train AI models. Federated learning has been described as being born at the intersection of AI, blockchain, edge computing and the Internet of Things.
Leasing allows healthcare facilities more freedom to acquire up-to-date medical equipment without the need for immediate capital investment, opening doors for smaller and newer enterprises.
A team at UPenn led by CAR-T pioneer Carl June used CRISPR/Cas9 to engineer T cells for treating multiple myeloma and sarcoma. Data on three patients were published in Science. All the patients' cancers ultimately progressed, though none had cytokine release syndrome.
NPR reported that the two patients, one with multiple myeloma and one with sarcoma, had received the gene-edited cell therapy as part of a Phase I trial.
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
A manufacturing error during a clinical trial of Kymriah, now marketed by Novartis, is less likely today, but could be an issue as CAR-Ts move into earlier therapy lines.
In the past, organs exposed to hepatitis C were typically discarded or given only to patients who already had the illness. Using them in patients who don’t have the virus could shorten the transplant wait time for hundreds of patients each year.
The interest in improving the sustained use of wearables goes beyond employer programs, according to the Annals of Internal Medicine study. It also applies to data collection for precision medicine initiatives to better target interventions.
At $475,000, the therapy isn't cheap but for its part, Novartis has said patients would only pay the full whack if they respond to the therapy by the end of the first month.
Can using wireless technology, financial incentives and social support improve medication adherence in heart attack survivors? A recent study published in JAMA Internal Medicine dives in.